Zenabis Group Sale and Investment Solicitation Process

Write-up content material

VANCOUVER, British Columbia — As beforehand declared on June 17, 2022, Zenabis Global Inc. (the “Corporation” or “Zenabis”) and its wholly-owned subsidiaries (collectively, the “Zenabis Team”) had been granted protection pursuant to an first order (as amended, the “Original Buy”) issued underneath the Companies’ Collectors Arrangement Act by the Excellent Court docket of the Province of Québec for the district of Montréal (the “Courtroom”). The Original Buy appointed Ernst & Young Inc. as keep track of (the “Keep track of”). On July 5, 2022, the Zenabis Team gained Courtroom approval for a sale and investment solicitation course of action (the “SISP”) to be carried out by the Observe.

Short article content

The Zenabis Group is a vertically integrated accredited cultivator of large-quality health care and leisure hashish. The Zenabis Team operates from its non-unionized indoor cultivation and processing facility in Atholville, New Brunswick. Via its proprietary brand names – Zenabis (healthcare cannabis), Namaste (leisure hashish) and Re-Up (recreational cannabis) – the Zenabis Team has effectively commercialized several genetic cannabis strains, tailored to precise buyer needs. Zenabis’ solution offering extends to dried flowers, pre-rolled joints, vape cartridges, distillates, soft gels and oral sprays, in a variety of product or service packaging remedies.

All certified interested get-togethers will be furnished with an prospect to participate in the SISP. The SISP is meant to solicit curiosity in and chances for (i) one or far more gross sales or partial product sales of all, substantially all, or certain portions of the business enterprise, and/or (ii) an investment in, restructuring, recapitalization, refinancing or other type of reorganization of the Zenabis Team or its organization.

The SISP will be done as a two-phased process with the Stage 1 Non-Binding LOI Submission Deadline set for 5:00 p.m. E.T. on August 15, 2022.

Copies of the order approving the SISP and the SISP procedures may well be acquired from the Monitor’s website, at www.ey.com/ca/zenabis.

Further news releases in regard of the CCAA course of action will be presented on an ongoing basis as important.

View supply edition on businesswire.com: https://www.businesswire.com/news/residence/20220720005055/en/

Contacts

All those who are intrigued in participating in this SISP can speak to the Check to receive supplemental information at:

Ernst & Young Inc. – Court-Appointed Watch of Zenabis World-wide Inc. et al.
900 Boul. de Maisonneuve O., Bureau 2300
Montréal, Québec, H3A 0A8
[email protected]
1-855-941-7757

#distro